SEC Form 4 · accession 0001144204-18-014203
ANI PHARMACEUTICALS INC · ANIP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Tracy Marshbanks
Director
Period of report
Mar 8, 2018
Accepted (ET)
Mar 12, 2018 · 7:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001023024
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F4 | Mar 8, 2018 | S | 15,391 | $63.08 | D | 534,543 | I | See Footnote |
| Common StockF2,F4 | Mar 9, 2018 | S | 36,561 | $63.01 | D | 497,982 | I | See Footnote |
| Common StockF3,F4 | Mar 12, 2018 | S | 12,269 | $63.03 | D | 485,713 | I | See Footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This transaction was executed in multiple trades at prices ranging from $63.00 to $63.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2This transaction was executed in multiple trades at prices ranging from $63.00 to $63.29. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3This transaction was executed in multiple trades at prices ranging from $63.00 to $63.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4Held by FA Private Equity Fund IV, L.P., FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, The Productivity Fund IV Liquidating Trust, and The Productivity Fund IV Advisors Fund Liquidating Trust, which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1)